SIGN (SIGN) 24-hour volatility at 63.8%: Sharp correction follows speculative pump triggered by Kraken listing announcement
Bitget Pulse2026/04/17 02:11Volatility Overview
In the past 24 hours, the price of SIGN surged from a low of $0.01825 to a high of $0.0299, then retraced to the current $0.02034, with an amplitude of 63.8%. 24-hour trading volume soared to approximately $275 million (over 1000% increase compared to the previous day, Vol/MCap over 700%), which is far higher than the market cap of about $38 million, indicating unusually active trading; there was a net capital outflow of around $2.44 million, with 2 million SIGN net outflow on CEXs.
Brief Analysis of Abnormal Movement Causes
- Kraken officially listed SIGN on April 17, 2026, reducing trading friction, which attracted speculative inflows and drove the price pump, but also made profit-taking easier, resulting in high volatility on the listing day.
- Trading volume exploded by over 7 times, futures trading volume reached $337 million, accompanied by spot net outflows of $4.28 million, confirming that speculative pump-and-dump behavior dominated after the surge.
Market Opinions and Outlook
The mainstream sentiment on X community is bearish, believing a downward channel has formed and distribution signs are evident, expecting further tests of the $0.018-$0.016 support levels. Traders noted that the short-term downtrend has lasted more than 18 hours, with a maximum decline of over 43% and weak rebounds. The short-term outlook remains cautious, with high volatility and significant risk of further retracement.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
